Fagron wants to grow through targeted acquisitions. Our international scope and scale, with corresponding innovation capacity and cross-selling opportunities, creates a strong competitive advantage. We aim to partner with companies that are targeting the North, South and Central American markets, the EMEA region, South Africa and Israel.
Our focus lies with products, portfolio, assets and companies contributing to the advancement of personalized medicine, especially enterprises which drive and enable our business in the Brands& Essentials, Compounding, Academy and Niche Pharmaceuticals
Transaction type (Ventures only)
Our typical transaction values go up to €5 million, which includes a wide range of financial instruments, amongst others convertible loans, growth-capital and co-investments alongside existing venture capital initiatives.